S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:ARDS

Aridis Pharmaceuticals Stock Forecast, Price & News

$5.54
-0.08 (-1.42 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.70
Now: $5.54
$5.81
50-Day Range
$5.62
MA: $7.02
$8.10
52-Week Range
$3.80
Now: $5.54
$10.18
Volume32,210 shs
Average Volume25,093 shs
Market Capitalization$55.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.18
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.
Aridis Pharmaceuticals logo

Headlines

Aridis Pharmaceuticals Announces Third Quarter 2020 Results
November 20, 2020 |  finance.yahoo.com
Aridis Pharmaceuticals to raise $8.5M in direct offering
October 14, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDS
CUSIPN/A
CIKN/A
Phone(408) 385-1742
Employees25
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.02 million
Book Value$0.41 per share

Profitability

Net Income$-29,680,000.00

Miscellaneous

Market Cap$55.77 million
Next Earnings Date4/14/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.16 out of 5 stars

Medical Sector

913th out of 1,968 stocks

Pharmaceutical Preparations Industry

436th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$5.54
-0.08 (-1.42 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARDS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

Is Aridis Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aridis Pharmaceuticals stock.
View analyst ratings for Aridis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Aridis Pharmaceuticals?

Wall Street analysts have given Aridis Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aridis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a increase in short interest in February. As of February 12th, there was short interest totaling 12,300 shares, an increase of 66.2% from the January 28th total of 7,400 shares. Based on an average trading volume of 19,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.2% of the shares of the company are sold short.
View Aridis Pharmaceuticals' Short Interest
.

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, April 14th 2021.
View our earnings forecast for Aridis Pharmaceuticals
.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) posted its quarterly earnings results on Thursday, November, 19th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.10.
View Aridis Pharmaceuticals' earnings history
.

How has Aridis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aridis Pharmaceuticals' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARDS shares have decreased by 14.2% and is now trading at $5.54.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARDS?

4 Wall Street analysts have issued 1-year price objectives for Aridis Pharmaceuticals' stock. Their forecasts range from $11.00 to $22.00. On average, they expect Aridis Pharmaceuticals' stock price to reach $17.00 in the next year. This suggests a possible upside of 206.9% from the stock's current price.
View analysts' price targets for Aridis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the following people:
  • Dr. Eric J. Patzer, Exec. Chairman (Age 72, Pay $233.12k)
  • Dr. Vu L. Truong, Founder, CEO & Director (Age 57, Pay $652.5k)
  • Mr. Fred Kurland, Consultant (Age 70, Pay $226.19k)
  • Mr. Michael A. Nazak, Chief Financial Officer (Age 62)
  • Mr. Jeffrey J. Fessler Esq., J.D., Acting Gen. Counsel (Age 58)
  • Dr. Hasan Jafri M.D., Chief Medical Officer

Who are some of Aridis Pharmaceuticals' key competitors?

What other stocks do shareholders of Aridis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include 1877 (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX).

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Who are Aridis Pharmaceuticals' major shareholders?

Aridis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Minot Wealth Management LLC (1.31%) and Worth Venture Partners LLC (0.87%).

Which major investors are buying Aridis Pharmaceuticals stock?

ARDS stock was purchased by a variety of institutional investors in the last quarter, including Minot Wealth Management LLC, and Worth Venture Partners LLC.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $5.54.

How much money does Aridis Pharmaceuticals make?

Aridis Pharmaceuticals has a market capitalization of $55.77 million and generates $1.02 million in revenue each year. The company earns $-29,680,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis.

How many employees does Aridis Pharmaceuticals have?

Aridis Pharmaceuticals employs 25 workers across the globe.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is www.aridispharma.com.

Where are Aridis Pharmaceuticals' headquarters?

Aridis Pharmaceuticals is headquartered at 5941 Optical Ct, San Jose CA, 95138.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at (408) 385-1742 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.